Vycor Medical annual revenue up 17% to $1.86M; operating profit swings to positive

VYCOR MEDICAL INC

Total revenue $1,863,400 (+17% YoY); Vycor Medical division $1,796,070 (+18%), driven by international growth.
GAAP operating profit of $33,900 vs loss of $9,145 in 2024; non-GAAP operating profit $145,881 (+79%).
Gross margin 83% vs 89% in 2024 due to higher costs and international sales mix.
NovaVision revenue $67,330 (-8% YoY); study validated NeuroEyeCoach for home use.
Seven new peer-reviewed VBAS studies published in 2025; total clinical papers reach 50.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

VYCOR MEDICAL INC reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 31, 2026, we issued a press release regarding our financial results for the year ended December 31, 2025.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

VYCOR MEDICAL INC filing history →

Source: SEC EDGAR

accession 0001493152-26-014079

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.